Print Page | Sign In | Join Today
News & Press: Company News

Cavion LLC Closes $5M Round of Convertible Debt

Wednesday, November 11, 2015  
Share |
Cavion LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of neurologic diseases and solid tumor cancers, has closed a $5 million private placement of convertible notes with new and existing investors. The proceeds will be used to expand Cavion’s platform of T-type calcium channel inhibitors through licensing and the development of new chemical entities and to support clinical trials in neurology and brain cancer. Cavion has raised over $18 million from private investors throughout the United States and received over $15 million in non-dilutive resources.

“Our investors appreciate Cavion’s mission to bring relief to patients suffering from cancer and neurologic diseases such as peripheral neuropathy and Parkinson’s,” stated Cavion President and CEO Andrew Krouse. “We are excited by their support for Cavion in this critical period as we develop multiple T-type calcium channel inhibitors and prepare for clinical trials in brain cancer and neurology that will launch in 2016.”

Our Premium Partners

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected